BioNTech (NASDAQ:BNTX) Upgraded by Evercore ISI to "Outperform" Rating

Evercore ISI upgraded shares of BioNTech (NASDAQ:BNTX - Free Report) from an in-line rating to an outperform rating in a research note issued to investors on Tuesday morning, MarketBeat Ratings reports. The firm currently has $125.00 price objective on the stock, up from their prior price objective of $110.00.

Other analysts have also recently issued research reports about the stock. Canaccord Genuity Group restated a "buy" rating and set a $171.00 price objective on shares of BioNTech in a research report on Thursday, November 14th. HC Wainwright reaffirmed a "buy" rating and set a $150.00 target price on shares of BioNTech in a report on Monday. TD Cowen reduced their target price on shares of BioNTech from $132.00 to $122.00 and set a "hold" rating on the stock in a report on Tuesday, November 5th. Hsbc Global Res raised shares of BioNTech from a "hold" rating to a "strong-buy" rating in a report on Friday, August 2nd. Finally, The Goldman Sachs Group raised shares of BioNTech from a "neutral" rating to a "buy" rating and increased their target price for the company from $90.00 to $137.00 in a report on Friday, November 8th. Four analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, BioNTech currently has an average rating of "Moderate Buy" and a consensus target price of $138.79.

BioNTech Price Performance

Shares of BioNTech stock traded up $4.53 on Tuesday, hitting $106.40. 1,104,105 shares of the company traded hands, compared to its average volume of 808,831. The firm's 50-day simple moving average is $113.68 and its 200 day simple moving average is $97.45. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The company has a market cap of $25.51 billion, a P/E ratio of -50.67 and a beta of 0.26. BioNTech has a 12-month low of $76.53 and a 12-month high of $131.49.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, beating the consensus estimate of ($1.26) by $2.07. The firm had revenue of $1.24 billion for the quarter, compared to analysts' expectations of $514.08 million. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The business's quarterly revenue was up 38.9% on a year-over-year basis. During the same quarter last year, the company posted $0.73 EPS. Analysts expect that BioNTech will post -3.68 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioNTech

A number of large investors have recently modified their holdings of the stock. Vestcor Inc bought a new stake in shares of BioNTech during the 3rd quarter valued at about $784,000. Y Intercept Hong Kong Ltd bought a new stake in shares of BioNTech during the 3rd quarter valued at about $718,000. XTX Topco Ltd bought a new stake in shares of BioNTech during the 3rd quarter valued at about $459,000. State Street Corp boosted its stake in shares of BioNTech by 2.0% during the 3rd quarter. State Street Corp now owns 155,867 shares of the company's stock valued at $18,512,000 after purchasing an additional 3,014 shares in the last quarter. Finally, Redmile Group LLC purchased a new position in BioNTech during the 3rd quarter valued at about $18,345,000. Institutional investors own 15.52% of the company's stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.